Autres langues Astria Therapeutics, Inc.

Actions

ATXS

US04635X1028

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
9,55 ^USD	+2,14%		+6,11%	+24,35%

23/04	ASTRIA THERAPEUTICS, INC. : HC Wainwright maintient sa recommandation à l'achat	ZM
09/04	Astria Therapeutics, Inc. nomme Sunil Agarwal à son conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05
Astria Therapeutics : - 2024 Proxy Statement	22/04
Astria Therapeutics : - 2023 Annual Report	22/04
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors	09/04
Astria Therapeutics, Inc. Appoints Sunil Agarwal to the Board of Directors and Member of the Science and Technology Committee	09/04
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/04
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04
Astria Therapeutics : Material Event - Form 8-K	25/03
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	25/03
Astria Therapeutics, Inc. Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE	25/03
North American Morning Briefing : Markets on Hold -2-	20/03
Astria Therapeutics, Inc.(NasdaqGM:ATXS) added to S&P Biotechnology Select Industry Index	18/03
Certain Stock Options of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	16/03
Certain Common Stock of Astria Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	16/03
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	06/03
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/03
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	04/03
Astria Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology Annual Meeting	21/02
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting	20/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Astria Therapeutics, Inc.

Actions

ATXS

US04635X1028

Autres langues

Filtres